Charles River Expands Alliances in Gene Therapy Manufacturing, Strengthening Capabilities and Services
In a move that further solidifies its position in the field of gene therapy manufacturing, Charles River Laboratories International, Inc. has announced a series of strategic alliances with leading institutions in the medical research and development sector. The company’s recent collaborations with the National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine), Wheeler Bio, Inc. and Pluristyx Inc. underscore Charles River’s commitment to expanding its portfolio of high-quality products and services in the evolving landscape of regenerative medicine.
The first alliance, a High Quality plasmid DNA development and manufacturing agreement with NUS Medicine, highlights Charles River’s focus on stem cell biology and therapy. As a leading medical education institution with expertise in this field, NUS Medicine brings valuable insights and capabilities to the collaboration. By utilizing the market-leading contract development and manufacturing organization (CDMO) services provided by Charles River, NUS Medicine aims to further enhance its research and development efforts in gene therapy.
The second alliance, formed with Wheeler Bio, Inc. centers around the preclinical and early clinical supply of recombinant proteins. Wheeler Bio is an antibody contract development and manufacturing organization (CDMO) that specializes in supporting biotechnology companies in their journey from discovery to manufacturing. Through this strategic agreement, clients of Charles River gain access to Wheeler Bio’s Portable CMC (Chemistry, Manufacturing and Controls) platform, enabling a more streamlined and efficient development process.
Lastly, Charles River’s collaboration with Pluristyx Inc. further expands its portfolio of human pluripotent stem cells. Pluristyx, a leading provider of tools, technologies, and services for the development of cell therapies, offers highly characterized and unique stem cell lines, including embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs). This partnership allows Charles River to leverage these valuable research tools in supporting the development of cell therapies and advancing regenerative medicine.
These alliances not only showcase Charles River’s dedication to innovation and scientific advancement but also highlight the company’s ability to forge strategic partnerships that enhance its capabilities and services. By joining forces with prominent institutions like NUS Medicine, Wheeler Bio, and Pluristyx, Charles River is positioned to deliver a comprehensive range of solutions to its clients, particularly early-stage biotechnology companies in need of quality contract development and manufacturing services.
The gene therapy landscape has seen tremendous growth in recent years, with significant advancements in the understanding and application of regenerative medicine. Charles River’s push to expand its alliances in this space demonstrates its commitment to staying at the forefront of industry trends and meeting the evolving needs of its clients.
In conclusion, Charles River’s recent collaborations with NUS Medicine, Wheeler Bio, and Pluristyx not only strengthen its position as a leader in gene therapy manufacturing but also position the company to offer a broader range of high-quality solutions to its clients. With a focus on stem cell biology and therapy, preclinical and early clinical supply of recombinant proteins, and the development of cell therapies, Charles River is well-equipped to support the growing demand for innovative solutions in regenerative medicine.
Comments